Elligint Health has acquired Laguna Health, a conversational AI company, in a move that will embed ambient documentation, quality assurance, and autonomous outreach capabilities across the Helios® care management platform serving 13 million managed lives. The deal signals a strategic shift toward AI-native care management infrastructure, combining three distinct AI engines that address the full member engagement lifecycle—from pre-call preparation through post-encounter documentation and proactive population health outreach.

Laguna Health will operate as a wholly owned subsidiary while maintaining independent commercial availability, allowing health plans to deploy its AI tools either as standalone modules within existing third-party systems or natively within the Helios ecosystem.

Three AI Engines Covering the Care Management Lifecycle

The acquisition brings three distinct products into Elligint's portfolio. Laguna Companion serves as an ambient AI co-pilot that handles pre-call preparation, provides live call support, and automates post-call documentation. Laguna Insight functions as a quality assurance engine that audits 100% of member calls against plan-specific clinical standards—a significant departure from traditional manual spot-check approaches. The platform was recognized among TIME's Best Inventions of 2024.

The third component, LISA, represents an agentic AI assistant capable of autonomous member outreach, conducting health assessments, and executing warm handoffs to human care managers when clinical judgment is required. According to the announcement, the technology achieves 99% clinical content accuracy in member conversation documentation and is supported by peer-reviewed randomized controlled trial evidence published in the Journal of Healthcare Management.

Documented Operational Impact at Scale

Real-world deployment data suggests meaningful efficiency gains. A multi-state health plan customer reduced care manager documentation time by 66%, according to the company. This reduction translates directly to increased capacity for complex case management without additional hiring—a critical consideration as health plans face persistent workforce shortages and rising member acuity.

The zero-integration deployment model for standalone use removes a traditional barrier to adoption, while native Helios integration is planned to begin with Laguna Companion. Elligint's Helios platform currently serves managed lives across all 50 U.S. states, providing immediate distribution scale for Laguna's technology.

Implications for Care Management Technology

The acquisition reflects broader industry movement toward integrated AI-native platforms rather than point solutions. By preserving standalone deployment options alongside native integration, Elligint acknowledges that health plans operate heterogeneous technology stacks and may prefer modular adoption pathways.

Leadership continuity appears central to the integration strategy—Laguna Health co-founder and CEO Yoni Shtein and co-founder Yael Peled Adam will remain with the organization. The company, founded in 2020 with operations in Edison, New Jersey and Tel Aviv, brings both clinical validation credentials and production deployment experience to Elligint's existing care management and utilization management technology portfolio.

For health plans, the combination addresses three operational bottlenecks simultaneously: pre-call preparation inefficiency, incomplete quality auditing traditionally limited to manual sampling, and constrained capacity for proactive member outreach. The autonomous outreach capability enables population-scale engagement rather than risk-stratified subsets, potentially expanding access to preventive interventions for historically underserved member segments.

Sources

  1. Elligint Health Acquires Laguna Health to Embed Conversational AI Across 13 Million Managed Lives — HIT Consultant